Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 7, 2021; 27(41): 7173-7189
Published online Nov 7, 2021. doi: 10.3748/wjg.v27.i41.7173
Published online Nov 7, 2021. doi: 10.3748/wjg.v27.i41.7173
Comprehensive radiomics nomogram for predicting survival of patients with combined hepatocellular carcinoma and cholangiocarcinoma
You-Yin Tang, Zhe-Yu Chen, Department of Liver Surgery, Liver Transplantation Center, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China
Yu-Nuo Zhao, Xue-Lei Ma, Department of Biotherapy, West China Hospital and State Key Laboratory of Biotherapy, Sichuan University, West China Hospital, Chengdu 610041, Sichuan Province, China
Tao Zhang, West China School of Medicine of Sichuan University, Chengdu 610041, Sichuan Province, China
Author contributions: Tang YY and Zhao YN provided the study concept and designed this study; Tang YY acquired the data; Zhang T and Zhao YN carried out data analysis and interpretation; Tang YY and Zhang T were responsible for drafting and preliminarily revising the manuscript; Ma XL and Chen ZY performed study supervision and final approval.
Institutional review board statement: This retrospective study was approved by the West China Hospital Ethics Committee (Approval No. 2019903).
Conflict-of-interest statement: The authors declare that they have no competing interests as defined by Nature Research, or other interests that might be perceived to influence the results and/or discussion reported in this paper.
Data sharing statement: The clinical data and radiomics data were available from the corresponding author at Chenzheyu@scu.edu.cn. And no additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zhe-Yu Chen, PhD, Chief Doctor, Full Professor, Postdoc, Surgeon, Surgical Oncologist, Department of Liver Surgery, Liver Transplantation Center, West China Hospital of Sichuan University, No. 37 Guoxue Street, Wuhou District, Chengdu 610041, Sichuan Province, China. chenzheyu@scu.edu.cn
Received: April 2, 2021
Peer-review started: April 2, 2021
First decision: June 24, 2021
Revised: June 26, 2021
Accepted: September 3, 2021
Article in press: September 3, 2021
Published online: November 7, 2021
Processing time: 217 Days and 13.6 Hours
Peer-review started: April 2, 2021
First decision: June 24, 2021
Revised: June 26, 2021
Accepted: September 3, 2021
Article in press: September 3, 2021
Published online: November 7, 2021
Processing time: 217 Days and 13.6 Hours
Core Tip
Core Tip: Combined hepatocellular carcinoma (HCC) and cholangiocarcinoma (cHCC-CCA) is defined as a single nodule showing differentiation into HCC and intrahepatic cholangiocarcinoma. Studies vary regarding the prognosis of cHCC-CCA patients after potentially curative hepatectomy, with 5-year postoperative overall survival rates ran